For a client who has been off all prescribed psychotropic medications for two weeks, reports feeling fine, wants to discontinue them permanently, and has a supportive relative, what is the recommended plan for safely tapering and monitoring the discontinuation?

Recommendation for Psychotropic Medication Discontinuation

Since this client has already been off all psychotropic medications for two weeks and reports feeling well, the immediate priority is to establish close clinical monitoring rather than restart medications, while obtaining a complete medication and symptom history to assess relapse risk and determine the appropriate follow-up schedule.

Critical First Steps

Obtain Complete History Before Making Final Decisions

Before proceeding with permanent discontinuation, you must gather essential information 1:

• Original diagnoses and symptom severity - What specific disorders were being treated?
• Previous medication trials and responses - Which medications were prescribed and at what doses?
• History of prior discontinuation attempts - Has the client stopped before? What happened?
• Baseline functional impairment - Was the client significantly impaired or suicidal before starting medications?
• Duration of treatment and symptom remission - How long was the client stable on medications?

Critical pitfall: Many patients and families cannot accurately describe the original symptoms or severity. Review medical records and contact previous prescribers if possible 1. This prevents exposing the patient to "needless and unexpected return of symptoms" 1.

Assess Current Withdrawal Risk

The client has been off medications for only two weeks. This is insufficient time to determine if discontinuation will be successful 1. Different medication classes and psychiatric conditions have vastly different relapse timelines:

• ADHD symptoms: May return within hours to days 1
• Mood and anxiety disorders: Symptoms can recur weeks to months after the last dose 1
• Anxiety disorders: Low relapse risk if asymptomatic for 6-12 months post-discontinuation 1
• Major depression: High recurrence risk, especially with 3+ lifetime episodes 2

The fact that the client feels "fine" at two weeks does not predict long-term success.

Monitoring Plan

Frequency of Visits During Discontinuation Phase

Patients actually need MORE frequent visits during discontinuation than during maintenance treatment 1. The AACAP guidelines explicitly state that close monitoring during dose reduction and for a period thereafter is essential to detect withdrawal symptoms and early relapse 1.

Recommended schedule:

• Weeks 2-8: Weekly or biweekly visits to monitor for emerging symptoms
• Months 2-6: Monthly visits, with more frequent contact before high-stress periods (e.g., return to school)
• Months 6-12: Every 2-3 months if remaining asymptomatic
• Beyond 12 months: Consider low-frequency monitoring based on disorder type and recurrence risk 1

What to Monitor

At each visit, systematically assess:

• Return of original target symptoms using rating scales when possible 1
• Withdrawal symptoms specific to the medication classes that were stopped 1
• Functional status - school performance, social relationships, daily activities
• Sleep, appetite, energy levels
• Safety concerns - suicidal ideation, risk-taking behaviors

Addressing the Client's Perspective

The "Never Needed Them" Belief

The client states he "did not need them when first started" and "continues to feel he does not need them now." This requires careful exploration:

If medications were truly unnecessary (misdiagnosis, overtreatment):

• Continued monitoring off medications is appropriate
• Document baseline functioning for comparison

If medications were necessary and effective:

• The client may be experiencing the "paradox of successful treatment" - feeling well because of medications, not despite them
• Education about relapse risk is critical 3, 4

Collaborative Decision-Making

The client and family's desire to discontinue must be respected within a shared decision-making framework 4, 2. The 2026 ASCP consensus emphasizes that deprescribing decisions should involve active patient participation 4. However, this collaboration requires:

• Full disclosure of relapse risks specific to the client's diagnoses 1
• Agreement on monitoring plan and what to do if symptoms return 1
• Clear understanding that feeling well now doesn't guarantee continued wellness 1

Specific Considerations by Medication Class

Since you don't specify which psychotropics were discontinued, consider these class-specific issues:

If Antidepressants Were Stopped

• Withdrawal symptoms can mimic relapse 5, 6
• Abrupt discontinuation doubles relapse risk compared to gradual taper 6
• If treating MDD with 3+ lifetime episodes, indefinite maintenance is typically recommended 2

If Stimulants Were Stopped (for ADHD)

• Symptom return may be rapid but school is not in session, masking functional impairment 1
• Critical to reassess when academic demands resume

If Mood Stabilizers Were Stopped

• Relapse can occur months after discontinuation 1
• Lithium discontinuation carries particular risk of rebound mania 1

If Antipsychotics Were Stopped

• Gradual withdrawal over >1 month is recommended to avoid withdrawal dyskinesias, parkinsonian symptoms, or neuroleptic malignant syndrome 3, 7
• Abrupt cessation increases relapse risk 7

If Benzodiazepines Were Stopped

• Abrupt discontinuation risks seizures, delirium tremens, and rarely death 8, 9
• The client may have already experienced dangerous withdrawal if stopped abruptly

The Retroactive Taper Problem

The client has already stopped abruptly, which is not recommended practice 3, 1, 9, 1. Guidelines consistently recommend gradual tapering over weeks to months 3, 1, 9, 1. However, since two weeks have passed:

• Do not restart medications just to taper properly if the client is currently stable
• Intensify monitoring for both withdrawal effects and symptom recurrence
• Educate about warning signs that would warrant immediate contact

Documentation and Safety Planning

Document clearly:

• Client and family's informed decision to remain off medications
• Risks discussed (relapse, withdrawal, functional decline)
• Monitoring plan agreed upon
• Safety plan if symptoms return, including:
  • Specific symptoms that warrant immediate contact
  • After-hours crisis resources
  • Agreement to restart medications if clinically indicated

If the client or family refuses adequate monitoring, this creates a barrier that increases risk 1. In such cases, document the refusal and consider whether you can ethically continue as the prescriber without ability to monitor outcomes 1.

When Permanent Discontinuation May Be Appropriate

Based on recent expert consensus 4, 2, deprescribing is most appropriate when:

• Medications produced <25% symptom improvement despite adequate trials
• Treatment goals have been reached AND relapse prevention is not a long-term objective
• The client has remained asymptomatic for a disorder-appropriate duration off medications
• Risk-benefit ratio has shifted unfavorably

This client does not yet meet criteria for confirmed successful discontinuation - only two weeks have passed without adequate monitoring of the discontinuation process.